<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547923</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-380</org_study_id>
    <secondary_id>2008-000026-39</secondary_id>
    <nct_id>NCT01547923</nct_id>
  </id_info>
  <brief_title>Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines</brief_title>
  <acronym>DPD c√¥lon</acronym>
  <official_title>The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICO Paul Papin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICO Paul Papin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate the medical and financial benefit of pre-therapeutic
      screening of DPD deficiency for predicting toxicity to fluoropyrimidines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fluoropyrimidines, of which 5-Fluorouracil is the most important, represent a family of
      medication that is used in particular in cancerology. They are molecules widely used in
      cancerology since they can be found in nearly 45% of chemotherapy protocols and in the
      treatment of about 50% of cancers (colorectum, oesophagus, stomach, breast, upper digestive
      and respiratory tracts). They are not only used in metastatic situations but also more and
      more in adjuvant situations, in other words for patients treated for a localised tumour,
      presenting a risk of relapse. A severe toxic risk cannot be tolerated in these conditions,
      and the doctor should assure the maximum level of safety for his patients. These medicines
      are the cause of 3% of grade IV toxicity from the first or second administration, and for
      0.3% of deaths. To this one can add on a total of 20 to 25% grade III-IV toxic events.

      Anticancer treatment is mostly administered by body size and in the best of cases after a few
      basic biological examinations such as a haemogram and renal status, without taking into
      consideration any individual particularities, whether genetic or epigenetic. Among potential
      toxicity risk factors one can find individual metabolic differences linked to genetic
      modifications of metabolism enzymes as well as differences in the chemical receptors and
      transporters.

      For fluoropyrimidines, a polymorphism was found for the dihydropyrimidine dehydrogenase gene
      (DPD), a major catabolism enzyme. A deficit of this enzyme is a major counter-indication for
      the use of these medicines.

      Early determination of DPD status would allow identification of patients at risk and would
      thus help in subsequent dose adjustment or selection of other treatment modalities.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and nature of grade IV toxicity.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>The percentage of severe toxicity (grade IV) will be analyzed in each arm. We expect a reduction of the early, severe, grade IV acute side-effects from 3% to 0.6% in the detected group with adapted doses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of grade III-IV toxic events.</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>We expect a reduction of the number of grade III-IV toxic events, whenever they occur, from 25% to 5% in the detected group with adapted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate.</measure>
    <time_frame>up to 6 months.</time_frame>
    <description>The current mortality rate of 3 per thousand patients will be cut to 0 in the detected group with adapted doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical-financial study of pre-therapeutic screening.</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>We will carry out a comparison of the prevention costs and the costs related to treating patients with toxicity. Direct costs and indirect costs will be taken into account.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2296</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Intravenous 5 Fluorouracile</condition>
  <arm_group>
    <arm_group_label>A : pre-therapeutic screening for DPD deficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : no pretherapeutic research of DPD deficiency</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample for phenotypic and pharmacogenetic analysis.</intervention_name>
    <description>Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).</description>
    <arm_group_label>A : pre-therapeutic screening for DPD deficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample for phenotypic and pharmacogenetic analysis.</intervention_name>
    <description>Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.</description>
    <arm_group_label>B : no pretherapeutic research of DPD deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  colorectal cancer, histologically confirmed, with all types included (including
             adjuvant cases), requiring treatment with intravenous 5-fluorouracil.

          -  anterior chemotherapy authorised, with the exception of chemotherapy containing a
             derivate of 5-Fluorouracil

          -  Age &gt; or = 18 years

          -  WHO Performance status &lt; or = 2

          -  Haematologic and hepatic parameters : neutrophils &gt; or = 1000 /mm3, platelets &gt; or =
             100000/mm3, Total bilirubin &lt; or = 2 x ULN, AST and ALT &lt; or = 3 x ULN, APL &lt; or = 5 x
             ULN

          -  Complete initial assessment before first treatment administration for imaging and
             pharmacogenetic, within 15 days for biology, and within 7 days for clinical
             examination.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Prior chemotherapy with fluoropyrimidines

          -  Symptomatic or uncontrolled ventral nervous system metastases

          -  Psychiatric Disease disrupting the trial understanding and the enlightened and
             voluntary consent character

          -  Patient who is pregnant or breast feeding

          -  Woman not consenting to use adequate contraceptive precautions during the study

          -  Patient who can not submit itself to the formal follow-up for psychological, social,
             family or geographical reasons

          -  Significant serious pathology or any instable medical condition (cardiac pathology
             uncontrolled, myocardial infarction within 6 months before enrollment, systemic active
             uncontrolled infection)

          -  any investigational agent within 4 weeks before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Capitain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Paul Papin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Berger, MD, PhD</last_name>
    <phone>33 2 41 35 27 34</phone>
    <email>virginie.berger@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessy Delaye, M Sc</last_name>
    <phone>33 2 41 35 29 31</phone>
    <email>jessy.delaye@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Capitain, MD, PhD</last_name>
      <email>olivier.capitain@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Capitain, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besan√ßon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Borg, MD</last_name>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H√©l√®ne Simon, MD</last_name>
      <email>helene.simon@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>H√©l√®ne Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU C√¥te de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Bouhier Leporrier, MD</last_name>
      <email>bouhierleporrier-k@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Karine Bouhier Leporrier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre Galais, MD</last_name>
      <email>mp.galais@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre Galais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P√¥le Sant√© L√©onard de Vinci</name>
      <address>
        <city>Chambray-les-Tours</city>
        <zip>37175</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Etienne Cailleux, MD</last_name>
      <email>pe.cailleux@oncologie37.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Etienne Cailleux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Haut Anjou</name>
      <address>
        <city>Chateau-Gontier</city>
        <zip>53204</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Val√©rie Rossi, MD</last_name>
      <email>vrossi@ch-hautanjou.fr</email>
    </contact>
    <investigator>
      <last_name>Val√©rie Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Cholet</city>
        <zip>49325</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medhi Kaassis, MD</last_name>
      <email>mehdi.kaassis@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>Medhi Kaassis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des C√®dres</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Roque, MD</last_name>
      <email>isa.roque@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Roque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H√¥pital Henri Mondor</name>
      <address>
        <city>Cr√©teil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Baumgaertner, MD</last_name>
      <email>isabelle.baumgaertner@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Baumgaertner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sarthe et Loir</name>
      <address>
        <city>La Fl√®che</city>
        <zip>72205</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic Rosenfeld, MD</last_name>
      <email>lorensefeld@pole-pssl.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Les oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85929</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Faroux, MD</last_name>
      <email>roger.faroux@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Roger Faroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Laval</city>
        <zip>53015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Stampfli, MD</last_name>
      <email>claire.stampfli@chlaval.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Stampfli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oana Cojocarasu, MD</last_name>
      <email>ocjocarasu@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Oana Cojocarasu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>53020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Amela, MD</last_name>
      <email>e-amela@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Amela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C√©lia Roemer-Becuwe, MD</last_name>
      <email>celia.becuwe@laposte.net</email>
    </contact>
    <investigator>
      <last_name>Celia Roemer Becuwe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Matysiak, MD</last_name>
      <email>tamara.matysiakbudnik@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Tamara Matysiak Budnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Fran√ßois, MD</last_name>
      <email>eric.francois@nice.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Fran√ßois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien Taieb, MD</last_name>
      <email>julien.taieb@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Taieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre B√©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C√©cile Fournel-Federico, MD</last_name>
      <email>cecile.fournel-federico@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>C√©cile Fournel Federico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saumur</city>
        <zip>49403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V√©ronique Gu√©rin-Meyer, MD</last_name>
      <email>veronique.guerin-meyer@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>V√©ronique Gu√©rin-Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Ren√© Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaafar Bennouna, MD</last_name>
      <email>jaafar.bennouna@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jaafar Bennouna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Delord, MD</last_name>
      <email>delord.jean-pierre@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Delord, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H√¥pital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Couteau, MD</last_name>
      <email>couteau.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne Couteau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lecomte, MD</last_name>
      <email>lecomt_t@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lecomte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>DihydroPyrimidine Dehydrogenase</keyword>
  <keyword>Lethal toxicity</keyword>
  <keyword>Fluoropyrimidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

